Lack of understanding leads to missed heart treatment opportunities
Poor awareness of a condition known as Heart Failure with preserved Ejection Fraction (HFpEF) – the cause of a half of all cases of heart failure in England… read more.
Poor awareness of a condition known as Heart Failure with preserved Ejection Fraction (HFpEF) – the cause of a half of all cases of heart failure in England… read more.
Article written by Gary Finnegan Thirty years after German reunification, stark differences remain in the health of citizens in the former East Germany and former West Germany.
Interview and article by Christine Clark Two programmes comprising training materials and back-up resources, have been essential for the development of effective practice pharmacy services that deliver meaningful… read more.
A Pesco-Mediterranean diet rich in plants, nuts, whole grains, extra-virgin olive oil, and fish and/or seafood is ideal for optimizing cardiovascular health, according to a cumulative review published… read more.
Heart attack patients who are sarcastic or irritable could be putting their health at risk, according to research published today in the European Journal of Cardiovascular Nursing, a journal… read more.
Article written by Bruce Sylvester Researchers from a large European study, which included the UK, report that while patients are often able to reduce risks of cardiovascular events… read more.
Article written by Peter Mas-Mollinedo E-cigarette use significantly increases a person’s risk of developing chronic lung diseases..
Merck Inc., announced that the FDA has accepted for priority review the New Drug Application (NDA) for BAY 1021189 (vericiguat), an orally administered soluble guanylate cyclase (sGC) stimulator,… read more.
Boehringer and Eli Lilly announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials related to exercise ability and symptom improvement with Jardiance (empagliflozin) in adults with chronic heart… read more.
Teleflex Incorporated announced the first patient enrollment in a clinical study that will evaluate the performance of Teleflex coronary guidewires and specialty catheters in Chronic Total Occlusion (CTO)… read more.
Esperion announced that the European Commission approved the Nilemdo (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine. Nilemdo is a first-in-class ATP Citrate Lyase (ACL)… read more.
Esperion announced the European Commission approved the Nustendi (bempedoic acid and ezetimibe) tablet, an oral, once-daily, non-statin LDL-cholesterol (LDL-C) lowering medicine for hypercholesterolemia and dyslipidemia in Europe. Nustendi… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.